JP MORGAN/CALL/MEDTRONIC/90/0.1/20.12.24 Share Price

Warrant

DE000JT221X3

Market Closed - Bid/Ask 07:11:32 04/07/2024 pm IST Pre-market 11:30:19 am
0.085 EUR -5.56% Intraday chart for JP MORGAN/CALL/MEDTRONIC/90/0.1/20.12.24 0.111 +30.59%
Current month-22.73%

Comparison chart between the derivative product and it's underlying value

End-of-day quotes
Date Price Change
04/24/04 0.085 -5.56%
03/24/03 0.09 +9.76%
02/24/02 0.082 -31.67%
01/24/01 0.12 +9.09%
28/24/28 0.11 -15.38%

Delayed Quote Börse Stuttgart

Last update July 04, 2024 at 07:11 pm IST

More quotes

Static data

Product typeWarrants
Buy / SellCALL
Underlying MEDTRONIC PLC
Issuer J.P. Morgan
WKN JT221X
ISINDE000JT221X3
Date issued 25/06/2024
Strike 90 $
Maturity 20/12/2024 (169 Days)
Parity 10 : 1
Emission price 0.18
Emission volume N/A
Settlement règlement en espèces
Currency EUR

Technical Indicators

Highest since issue 0.16
Lowest since issue 0.082
Delta0.2x
Omega 12.86
Premium18.16x
Gearing65.18x
Moneyness 0.8574
Difference Strike 12.83 $
Difference Strike %+14.26%
Spread 0.041
Spread %31.54%
Theoretical value 0.1095
Implied Volatility 21.99 %
Total Loss Probability 84.01 %
Intrinsic value 0.000000
Present value 0.1095
Break even 91.18 €
Theta-0.01x
Vega0.01x
Rho0.01x

Company Profile

Medtronic plc is one of the world leaders in designing, manufacturing and marketing of medical equipment. Net sales break down by sector of activity as follows: - general and minimally invasive surgery (28.8%): surgical equipment, intra-operative monitoring systems, ventilation systems, etc.; - cardiac rhythm management (18.6%): implantable cardiac pacemakers, implantable defibrillators and automatic external defibrillators, cardiac ablation probes, etc.; - vascular diseases and cardiac surgery (17.4%): coronary stents, endoprostheses for aortal pathologies, distal protection systems, catheters, heart valve prostheses, auto-transfusion equipment, cardiac ablation devices, etc.; - spinal disorders (14.1%): spinal prostheses, disc prostheses, cerebral stimulation systems, bone graft technologies and mini-invasive spinal surgery, etc. The group also develops medical imagery-guided surgical navigation systems activity; - neurovascular, ear, nose and throat (ENT) and pelvic diseases (8.2%); - diabetes management (7.4%): internal and external glycemia monitoring systems and insulin pumps; - neurological disorders (5.5%): neurostimulation and pumped medication administration products, diagnostic tools, etc. Net sales are distributed geographically as follows: Ireland (0.3%), the United States (50.9%) and other (48.8%).
Sector
-
More about the company

Ratings for Medtronic plc

Trading Rating
Investor Rating
ESG Refinitiv
C
More Ratings

Consensus: Medtronic plc

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
33
Last Close Price
77.17 USD
Average target price
94.02 USD
Spread / Average Target
+21.84%
Consensus